Cadila Healthcare Ankleshwar facility successfully completes USFDA inspection
"The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22 to July 26, 2019," Cadila Healthcare added.
New Delhi: Drug firm Cadila Healthcare recently said it has received no observations from the US health regulator for the inspection of its manufacturing plant at Ankleshwar in Gujarat.
"Drug firm Cadila Healthcare on July 26 said its manufacturing plant at Ankleshwar in Gujarat has completed inspection by the US health regulator with no observations," the company said in a filing.
"The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22 to July 26, 2019," Cadila Healthcare added.
Read Also: Cadila Healthcare gets 11 USFDA observations for St Louis facilities
This audit covered both Units I and II. At the end of the inspection, no 483 observations were issued, it added.
Read Also: Cadila Healthcare gets EIR report on Ahmedabad SEZ facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd